Navigation Links
Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
Date:11/8/2011

BI 201335 on the background of 24 weeks of PegIFN/RBV was sufficient to achieve sustained viral response (SVR).  Patients with undetectable viral load prior to week 8 had similar SVR rates, whether they were treated for 12 or 24 weeks with BI 201335 (80 percent and 82 percent, respectively).

The most frequent adverse events (AEs) in SILEN-C3 were mild gastrointestinal disorders, rash, photosensitivity and jaundice due to isolated unconjugated hyperbilirubinemia.

In this open-label Phase 2 trial, 159 treatment-naive GT1 HCV patients were randomized to receive 120 mg BI 201335 once daily for 12 or 24 weeks, each after three days lead-in (LI) with PegIFN/RBV.  In both groups, PegIFN/RBV was given for 24 weeks.  Patients who did not have an eRVR continued PegIFN/RBV to week 48.  eRVR was defined as viral load less than 25 IU/mL at week 4 and undetectable at weeks 8-18.  In the 12 week treatment group, 72 percent of patients had an eRVR and in the 24 week treatment group, 82 percent of patients had an eRVR.

(Abstract #226) Treatment with the 2nd Generation HCV Protease Inhibitor BI 201335 Results in High and Consistent SVR Rates – Results from SILEN-C1 in Treatment-Naive Patients Across Different Baseline Factors

This analysis of SILEN-C1 evaluated SVR according to various baseline characteristics among patients who received BI 201335 240 mg once daily without LI.

The majority of patients with more difficult-to-treat HCV types – specifically GT1a and IL-28B non-CC allele patients – achieved SVR.  Among patients with GT1a HCV (n=32), a type that traditionally is associated with lower treatment response rates compared to GT1b, 82 percent achieved SVR.  Among GT1b HCV patients (n=38), 84 percent achieved SVR.  In addition, SVR was 71 percent for patients with non-CC alleles of the IL-28B gene (n=29).  Patients with CC alleles (n=11) or for whom IL-28B genotyping wa
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
6. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... Disorders Drug Pipeline Insight 2014" report to their offering. ... in US is one of the largest segments of pharmaceuticals ... alarming rate, while the available therapies were unable to meet ... in the market for CNS disorder, especially over the past ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Company to present interim results from phase 2 trial of novel ... ... NEW HAVEN, Conn., April 3, 2008 Rib-X Pharmaceuticals,Inc. ("Rib-X" ... of novel antibiotics for the treatment of,antibiotic-resistant infections, today announced that ...
... Proof-of-Principle Studies -, GAITHERSBURG, Md., April 3, ... announced that it has signed an agreement,with Merck ... the use of the Iomai needle-free immunostimulant patch., ... exclusive license. These,preclinical proof-of-principle studies will be conducted ...
Cached Medicine Technology:Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference 2Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch 2Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch 3
(Date:8/29/2014)... UWDress.com, one of the most famous dress ... of 2014 floor length bridesmaid dresses . Additionally, ... items. According to the company’s marketing specialist, all its ... rate (up to 60 percent off) before September 10. ... special neckline: strapless, one-shoulder, bateau and more. The main ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to new ... But Not Peer Pressure, Key to Prescription Drug Misuse Among ... primary focus for 18-29 year olds when it comes to ... the for this age group the real problem which influences ... drug associations and recreational use of them to have fun ...
(Date:8/29/2014)... Healthpointe is proud to welcome to ... will be practicing out of Healthpointe’s newest office directly ... Healthpointe’s orthopedic team, Dr. Rodas is board-certified ... in occupational medicine. , Among Dr. Rodas’ many ... of Raytheon, the world-class defense and aerospace company. Additionally, ...
(Date:8/29/2014)... regarded audiologist , Dr. Mary Ann Larkin has written 4 ... are titled:, , Revealing the Truth About Tinnitus ... The Top 5 Things You Should Know Before Buying a ... , Dr. Mary Anne Larkin choose to write about ... misinformation about each them. The reports are available for immediate ...
(Date:8/29/2014)... Healthpointe Medical Group, one of Southern California’s ... LAXMed. The medical center is less than 2 miles from ... the 405 freeway. , The LAX clinic marks the ... is located at: 8610 S. Sepulveda Blvd., Suite 204 Los ... LAX office will provide the same comprehensive services as Healthpointe’s ...
Breaking Medicine News(10 mins):Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... ... Pediatric Surgery , ... 16, 2009 -- Children,s National Medical Center today announced that it will create a new ... of Abu Dhabi. , , ,"This is a great day for Children,s National, but it,s ...
... , Pocono Medical Center and facilities ... of laboratory errors due to specimen mislabeling , ... northeast Pennsylvania have come together to reduce and eliminate laboratory errors ... effort when they noticed they were reporting a large number of ...
... FORT LAUDERDALE, Fla. and BEVERLY HILLS, Calif., Sept. 16 As ... for ways to supplement their income. In response, a new ... event at the Sofitel Hotel in Beverly Hills to introduce its ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090916/NY76803 ) , (Logo: ...
... , , , WASHINGTON, ... by U.S. Senate Finance Committee Chairman Max Baucus (D-MT) will ... health coverage, while letting insurance companies charge what they please ... the most successful insurance premium regulation law in the nation, ...
... , , ... Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced ... Trademark Office has issued a Notice of Allowance for Milestone,s ... Dynamic Pressure Sensing." , , ...
... ... CSL), one of the world,s leading manufacturers of influenza vaccine, announced that the U.S. ... licensure of its monovalent pandemic (H1N1) 2009 influenza A vaccine for active immunization of ... , ...
Cached Medicine News:Health News:New Surgery Institute at Children's National Medical Center Aims to Improve Surgery and Eliminate Pain 2Health News:New Surgery Institute at Children's National Medical Center Aims to Improve Surgery and Eliminate Pain 3Health News:New Surgery Institute at Children's National Medical Center Aims to Improve Surgery and Eliminate Pain 4Health News:Pennsylvania Patient Safety Authority Releases September Advisory 2Health News:Pennsylvania Patient Safety Authority Releases September Advisory 3Health News:Pennsylvania Patient Safety Authority Releases September Advisory 4Health News:Pennsylvania Patient Safety Authority Releases September Advisory 5Health News:livethesource(TM) Hosts Company Launch Event While Supporting The Brent Shapiro Foundation's Annual Sober Night Out 2Health News:livethesource(TM) Hosts Company Launch Event While Supporting The Brent Shapiro Foundation's Annual Sober Night Out 3Health News:Baucus Health Plan Won't Rein in Health Insurer Price Gouging of Middle Class; Consumer Watchdog Calls for 'Prior Approval' Rate Regulation in Health Reform 2Health News:Baucus Health Plan Won't Rein in Health Insurer Price Gouging of Middle Class; Consumer Watchdog Calls for 'Prior Approval' Rate Regulation in Health Reform 3Health News:Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office 2Health News:Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office 3Health News:Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office 4Health News:CSL Biotherapies Announces FDA Marketing Approval of its Monovalent Pandemic (H1N1) 2009 Influenza A Vaccine 2
... American Industrial Laboratories, Inc. specializes in ... eyebank and laboratory specular microscopes, digital ... camera digital upgrade package. Our software ... image data correlation with rapid image ...
... management software is a full-featured product ... clinical aspects of the ophthalmic practice. ... for the financial, administrative and clinical ... professional. Designed as a scaleable solution, ...
The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes...
... The 2V slit lamp ... slit lamp that is ... illumination tower and has ... magnification. Revolutionary design provides ...
Medicine Products: